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Abstract
Background: The increasing incidence of impaired glucose tolerance (IGT), gestational diabetes (GDM) and type 2
diabetes (T2D) during pregnancy was hypothesized to be associated with increases in pre-pregnancy body mass
index (BMI). The aims were to 1) determine the prevalence of IGT/GDM/T2 D over a 10 year period; 2) examine the
relationship between maternal overweight/obesity and IGT/GDM/T2D; and 3) examine the extent to which
maternal metabolic complications impact maternal and fetal pregnancy outcomes.
Methods: Data arose from a perinatal database which contains maternal characteristics and perinatal outcome for
all singleton infants born in London, Canada between January 1, 2000 and December 31, 2009. Univariable and
multivariable odds ratios (OR) were estimated using logistic regression with IGT/GDM/T2 D being the outcome of
interest.
Results: A total of 36,597 women were included in the analyses. Population incidence of IGT, GDM and T2 D rose
from 0.7%, 2.9% and 0.5% in 2000 to 1.2%, 4.2% and 0.9% in 2009. The univariable OR for IGT, GDM and T2 D were
1.65, 1.52 and 2.06, respectively, over the ten year period. After controlling for maternal age, parity and pre-
pregnancy BMI the OR did not decrease. Although there was a positive relationship between pre-pregnancy BMI
and prevalence of IGT/GDM/T2 D, this did not explain the time trends in the latter. Diagnosis of IGT/GDM/T2 D
increased the risk of having an Apgar score <7 at 5 minutes, which was partially explained by gestational
hypertension, high placental ratio, gestational age and large for gestational age babies.
Conclusions: We found a significant increase in the incidence of IGT/GDM/T2 D for the decade between 2000-
2009 which was not explained by rising prevalence of maternal overweight/obesity.
Background
Maternal glucose disorders (MGD) during pregnancy
include gestational diabetes mellitus (GDM), impaired
glucose intolerance (IGT) and pre-pregnancy type 2 dia-
betes. GDM is defined as glucose intolerance with onset
or first diagnosis during pregnancy [1,2]. This is a com-
mon disease affecting 3-4% of pregnancies in Canada
[1]. Recent data from the United States and Australia
have indicated that the prevalence of GDM is on the
rise. However, the underlying cause is unknown [3-12].
Postulated mechanisms include the concomitant rise in
obesity [12,13] and decrease in physical activity [14,15].
In 2000, 30% of American adults were obese (body mass
index (BMI) ≥30 kg/m
2) representing a 23% increase
over the previous decade [16]. In a study of nine US
states, the prevalence of maternal obesity increased
69.3% from 1993-2003 [17]. Several studies have demon-
strated that MGD is strongly related to maternal obesity
[18,19]. However, none of the studies previously exam-
ining the time trend of MGD had pre-pregnancy BMI
available in their database [3-11]. Therefore, ours is the
first to examine the relationship between pre-pregnancy
BMI and changes in the prevalence of MGD.
The objectives of the present study were: 1) to describe
the annual prevalence of MGD (including GDM, type 2
diabetes and IGT) over a 10 year period; 2) to examine
the relationship between annual prevalence of maternal
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the extent to which they are associated; and 3) to exam-
ine, at the individual level, the extent to which maternal
metabolic complications impact on maternal and fetal
pregnancy outcomes. We hypothesized that, between
2000-2009, the prevalence of maternal glucose disorders
will have increased, especially in women with a BMI ≥25
kg/m
2. It was also hypothesized that the time trend of
maternal glucose disorders would be explained by the
time trend of overweight/obesity. Finally, we hypothe-
sized that the offspring of pregnancies affected by mater-
nal glucose disorders would have an increased incidence
of pregnancy complications compared with the normal
obstetrical population.
Methods
The following protocol has been approved by the
Research Ethics Board for the Review of Health Sciences
Research Involving Human Subjects at the University of
Western Ontario. We conducted a retrospective cohort
study using data from the Saint Joseph’sH e a l t hC a r e
Perinatal Database which contains data from medical
records, including delivery and neonatal information.
Data from all births occurring in London, Canada are
prospectively collected and entered into this large peri-
natal database by a dedicated research assistant. The
study population was selected based on the following
criteria: delivery between January 1, 2000 and December
31, 2009 (n = 36,597), singleton pregnancy and resi-
dence in London, Canada. Women diagnosed with type
1 diabetes prior to pregnancy were removed from the
dataset. The following data were used for analyses:
maternal characteristics (age, parity, height (measured
during prenatal visit), pre-pregnancy weight (from
maternal recall), excessive weight gain, previous GDM
or pre-existing type 2 diabetes, pre-existing hyperten-
sion, gestational hypertension (including pregnancy
induced hypertension and pre-eclampsia), IGT and diag-
nosis of GDM - which may include previously undiag-
nosed type 2 diabetes), infant characteristics (gestational
age, birth and placental weight) and pregnancy out-
comes (type of delivery and Apgar scores). After the
data were checked for errors, all identification (including
names and hospital record numbers) was stripped to
ensure anonymity of the data. Large for gestational age
(LGA) and small for gestational age (SGA) were identi-
fied using Canadian birth weight for gestation distribu-
tions [20]. A ratio dividing placental weight (g) by infant
birth weight (g) was determined. Maternal pre-preg-
nancy weight and height were taken from medical
records. Maternal pre-pregnancy BMI was calculated
using pre-pregnancy weight (kg)/[height (m)]
2. Excessive
pregnancy weight gain was defined as weight gain from
pre-pregnancy weight to delivery weight ≥20 kg in the
database. Type 2 diabetes, GDM and IGT were taken
directly from diagnosis entered into the database. All
pregnant women in Canada are screened and diagnosed
for these diseases according to guidelines set by the
Canadian Diabetes Association [1,2].
All analyses were performed using the Statistical Ana-
lysis System 9.1.3 (SAS Institute, Cary, NC) and Statisti-
cal Package for the Social Sciences, version 16 (SPSS
Inc, Chicago, Ill). The annual prevalence of maternal
glucose disorders from 2000-2009 (Objective 1) within
strata (by year, body mass index (BMI), age and/or par-
ity) was estimated as a proportion and standard error of
the estimate. To address Objective 2, prevalence of
maternal glucose disorders by pre-pregnancy BMI cate-
gories (underweight (< 18.5 kg/m
2), normal weight
(18.5-24.9 kg/m
2), overweight (25-29.9 kg/m
2) and Class
I, II and III obese (30-34.9 kg/m
2, 35-39.9 kg/m
2 and
≥40 kg/m
2, respectively) were summarized using fre-
quency distributions. Repeated measures ANOVA was
used to determine the increase in overweight/obesity
over time. P < 0.05 indicates statistical significance. Uni-
variable and multivariable odds ratios were estimated
using logistic regression with the outcome of interest
being MGD (IGT, GDM and type 2 diabetes). Predictive
factors were entered in a blockwise fashion in order to
allow for a careful examination of the relative contribu-
tions of each predictive factor to the relationship
between year and MGDs. Year, maternal age and parity
were entered in the first block, BMI in the second block
and excessive weight gain in the third block. To address
objective 3, frequency distributions and mean ± SD of
1) IGT; 2) GDM; 3) type 2 diabetes; and 3) no metabolic
disorder were created. Univariable and multivariable
odds ratios were estimated using logistic regression with
the outcome of interest being Apgar <7 at 5 minutes
after birth. Apgar <7 at 5 minutes after birth was chosen
as a proxy for neonatal well-being, because a variety of
clinical events that affect the well-being of the infant
will be reflected in the Apgar score [21].
Results
We examined data from 36,597 women who gave birth
between Jan 1, 2000 and Dec 31, 2009 in London, Ontario,
Canada. Description of the sample follows with mean ±
standard deviation (min-max). The women were 29.5 ±
5.5 (14.1-47.9) years old, 165 ± 10 (103-195) cm tall, with
a pre-pregnancy body mass of 67.0 ± 15.9 (31.8 - 189.6) kg
and a pre-pregnancy BMI of 24.7 ± 5.5 (14.6-67.5) kg/m
2.
Pre-pregnancy BMI was unavailable for 8,611 women.
These women were not included in the analysis.
Incidence of maternal glucose disorders from 2000-2009
Pregnancies affected by type 2 diabetes increased signifi-
cantly from 0.5% in 2000 to 0.9% in 2009 (p = 0.001).
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same period from 2.9% to 4.2% (p = 0.002) and the pre-
valence of IGT increased from 0.7% to 1.2% (p = 0.001).
The prevalence of pre-pregnancy overweight and obe-
sity did not significantly change between 2000 and 2009
and were, respectively, 22.1% and 14.4% in 2000 and
22.2% and 16.0% in 2009. The p-values attached to
changes in prevalence were p = 0.79 for overweight and
p = 0.43 for obesity. Thus, there was not an association
with the time trend in MGT. However, ignoring time
trends, there was a positive relationship between BMI
and maternal glucose disorders in that as BMI category
increased, the prevalence of maternal glucose disorders
also increased (Table 1).
Univariable and multivariable associations of year,
maternal age, parity, BMI and excessive weight gain
with MGDs are presented in Table 2. Univariable ana-
lyses indicate a 65%, 52% and 206% increase in the pre-
valence of IGT (OR: 1.65, 95% CI: 1.12 - 2.43), GDM
(OR: 1.52, 95% CI: 1.25-1.83)) and type 2 diabetes (OR:
2.06, 95%CI: 1.29-3.27), respectively, for the decade
between 2000 and 2009 with a slight amplification of
these ORs after control for covariates. Therefore, the
increase in the prevalence of maternal glucose disorders
over time was not explained by BMI nor was it
explained by excessive pregnancy weight gain (IGT aOR:
2.09, 95% CI: 1.36-3.20; GDM aOR: 1.68, 95% CI: 1.35-
2.10; type 2 diabetes aOR 2.33, 95% CI: 1.38-3.92)
(Table 2). Strong univariable and multivariable associa-
tions were demonstrated between BMI and MGDs.
Maternal glucose disorders and pregnancy outcome
Diagnosis of IGT or GDM during pregnancy was asso-
ciated with an increased incidence of of LGA, caesarean
section delivery and gestational hypertension (Table 3)
whereas diagnosis of type 2 diabetes during pregnancy was
associated with increased frequency of LGA, Apgar <7 at 5
minutes, caesarean section delivery and gestational hyper-
tension. The incidence of SGA is slightly lower. Univari-
able analysis indicates that the risk of having an Apgar <7
at 5 minutes after delivery is higher in IGT (OR 1.87, 95%
CI: 1.36 - 2.56), GDM (OR 1.50, 95% CI: 1.27 - 1.77), type
2 diabetes (OR 2.99, 95% CI: 2.17 - 4.12), BMI ≥30 kg/m
2
(OR 1.54, 95% CI: 1.38 - 1.71), high placental ratio (OR
1.93, 95% CI: 1.76 - 2.12) and gestational hypertension
(OR 1.69, 95% CI: 1.51 - 1.89) (Table 4). After controlling
for maternal age, BMI, parity, type 2 diabetes, GDM and
excessive weight gain, multivariable analysis of factors
associated with Apgar at 5 minutes <7 were unchanged
(Table 4). Further multivariable analysis of factors asso-
ciated with Apgar at 5 minutes <7 indicated that the
increased risk of IGT, GDM and type 2 diabetes diagnosis
is partially explained by gestational hypertension, high pla-
cental ratio, gestational age and LGA (Table 4, multivari-
able model 3).
Discussion
The results indicated that in London, Canada the preva-
lence of maternal glucose disorders increased by 65%
for IGT, 52% for GDM and 206% for type 2 diabetes
between 2000 and 2009. While maternal glucose disor-
ders were shown to be associated with overweight and
obesity, the temporal increase in maternal glucose disor-
ders over the ten year period was not explained by simi-
lar increases in BMI. Examination of outcomes indicated
that being diagnosed with IGT, GDM and type 2 dia-
betes did increase the risk of having an Apgar score <7
at 5 minutes.
To our knowledge, this is the first study to analytically
examine the relationship between prevalence of mater-
nal glucose disorders and obesity over time. Nine stu-
dies previously examined the changing prevalence in
GDM during various time points between 1979 and
2005 [3-12]. One study found that the prevalence of
GDM was stable between 1999-2005 in a Southern Cali-
fornia population while the prevalence of type 2 diabetes
increased [11]. The remaining studies demonstrated an
increase in GDM that ranged from 12% [5] to 127% [4].
While each of these studies was able to examine the
influence of ethnicity on the rising prevalence of GDM,
most found that this increase was independent of ethni-
city or only partially explained by ethnicity. None of the
previous studies examining the time trend of maternal
glucose disorders had access to pre-pregnancy BMI to
determine if overweight/obesity played a role. As pre-
dicted by the literature, we found that elevated BMI was
a major risk factor for developing GDM [22]. However,
we also found that BMI ≥25 kg/m
2 did not increase
Table 1 Body mass index and metabolic disorders
< 18.5
(N = 1618)
18.5-24.9
(N = 15898)
25.0-29.9
(N = 6272)
30.0 - 34.9
(N = 2571)
35.0 - 39.9
(N = 1067)
> 40.0
(N = 560)
Previous GDM 9 (0.6%) 132 (0.8%) 129 (2.1%) 81 (3.2%) 58 (5.4%) 39 (7.0%)
Type 2 Diabetes 5 (0.2%) 52 (0.3%) 48 (0.8%) 28 (1.1%) 23 (2.2%) 23 (4.1%)
IGT 21 (1.3%) 110 (0.7%) 87 (1.4%) 37 (1.4%) 17 (1.6%) 11 (2.0%)
GDM 5 (0.3%) 316 (2.0%) 299 (4.8%) 193 (7.5%) 111(10.4%) 95 (17.0%)
Values are number diagnosed (%). GDM, gestational diabetes mellitus; IGT, impaired glucose tolerance.
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population. These results are surprising as they are in
contrast to Kim et al [17] who examined obesity rates
in nine US states and found that the prevalence of
maternal obesity (BMI >29 kg/m
2) and overweight (BMI
26.0 - 29.0 kg/m
2) increased by 69.3% and 18.6%
between 1993 and 2003, respectively. In the present
study, after controlling for maternal age, parity and pre-
pregnancy BMI, the impact of year was a 209% increase
in IGT, a 168% increase in GDM and a 233% increase
in pre-existing type 2 diabetes. These results suggest
that there are other important variables affecting the
prevalence of maternal glucose disorders. Postulated
mechanisms include physical inactivity or excessive
intake of dietary fat [23,24]. Further research is required.
The results of the univariable analyses in the present
study found that the risk of low Apgar scores was
related to diagnosis of IGT, GDM, T2 D, obesity,
Table 2 Univariable and multivariable analysis of factors associated with impaired glucose tolerance (IGT), gestational
diabetes mellitus (GDM) and type 2 diabetes
Univariable Multivariable Multivariable + BMI Multivariable + BMI +
Excessive Weight Gain
Year IGT 1.65 (1.12-2.43) 1.65 (1.12-2.43) 2.09 (1.36-3.20) 2.09 (1.36-3.20)
GDM 1.52 (1.25-1.83) 1.52 (1.12-2.43) 1.68 (1.35-2.10) 1.68 (1.35-2.10)
Type 2 2.06 (1.29-3.27) 2.07 (1.30-3.28) 2.33 (1.38-3.92) 2.34 (1.39-3.94)
Maternal Age (≥35 vs. <35) IGT 1.50 (1.13-1.96) 1.60 (1.22-2.10) 1.40 (1.03-1.9) 1.40 (1.03-1.9)
GDM 2.46 (2.18-2.77) 2.39 (2.12-2.70) 2.31 (2.01-2.66) 2.31 (2.0-2.65)
Type 2 2.11 (1.58-2.83) 2.07 (1.54-2.79) 1.97 (1.41-2.76) 1.99 (1.42-2.79)
Parity (≥ 1 vs. 0) IGT 0.82 (0.66-1.03) 0.77 (0.61-0.96) 0.75 (0.58-0.96) 0.75 (0.58-0.96)
GDM 1.31 (1.17-1.46) 1.13 (1.01-1.27) 0.95 (0.83-1.08) 0.94 (0.83-1.08)
Type 2 1.23 (0.94-1.61) 1.10 (0.84-1.44) 0.91 (0.67-1.23) 0.93 (0.69-1.26)
BMI (25.0-29.9 vs. <25.0) IGT 2.22 (1.69-2.94) 2.24 (1.69-2.92) 2.24 (1.69-2.96)
GDM 2.58 (2.21-3.03) 2.52 (2.15-2.96) 2.52 (2.15-2.96)
Type 2 2.54 (1.67-3.61) 2.41 (1.64-3.55) 2.41 (1.64-3.55)
BMI: (≥30.0 vs. <25.0) IGT 2.65 (1.95-3.6) 2.68 (1.97-3.65) 2.68 (1.97-3.65)
GDM 5.50 (4.74-6.39) 5.43 (4.67-6.31) 5.39 (4.63-6.27)
Type 2 6.03 (4.26-8.54) 5.96 (4.21-8.44) 6.11 (4.30-8.67)
Excessive Weight Gain (> 20 kg) IGT 1.06 (0.75-1.48) 1.00 (0.70-1.42)
GDM 0.77 (0.64-0.92) 0.91 (0.74-1.11)
Type 2 1.16 (0.79-1.71) 1.36 (0.90-2.05)
Multivariable analysis includes year, maternal age and parity.
Multivariable + BMI analysis includes year, maternal age, parity and BMI.
Predictive factors were entered in a blockwise fashion in order to allow for a careful examination of the relative contributions of each predictive factor to the
relationship between year and MGDs. Year, maternal age and parity were entered in the first block, BMI in the second block and excessive weight gain in the
third block.
Table 3 The impact of maternal glucose disorders on maternal and fetal pregnancy outcomes
IGT GDM T2D Normal
Percent or Mean Percent or Mean Percent or Mean Percent or Mean
N = 317 N = 1342 N = 224 N = 34714
Gestational Age (weeks) 38.7 ± 1.8 38.2 ± 1.9 37.1 ± 2.4 39.0 ± 2.0
Birth Weight (g) 3462 ± 568 3442 ± 637 3533 ± 806 3415 ± 577
Placental Weight (g) 699 ± 149 714 ± 200 736 ± 206 674 ± 171
Placental Ratio 0.2095 ± 0.0340 0.2095 ± 0.0411 0.2132 ± 0.0475 0.1993 ± 0.0421
LGA 18.6% 21.8% 43.8% 11.2%
SGA 6.6% 7.2% 2.7% 8.4%
Apgar 5 Minutes <7 2.5% 2.5% 3.1% 1.6%
C/S Delivery 31.2% 35.8% 57.1% 20.2%
gestational hypertension 15.5% 15.6% 28.1% 7.5%
Values are mean ± SD or number diagnosed (%). GDM, gestational diabetes mellitus; T2 D, type 2 diabetes; LGA, large for gestational age; SGA, small for
gestational age; Apgar, appearance, grimace, pulse, activity, respiration; C/S, caesarean.
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ever, after controlling for confounding factors, the low
Apgar scores associated with IGT, GDM and T2 D were
partially explained by concurrent diagnosis of gestational
hypertension, having a high placental ratio, gestational
age and delivering an LGA infant. It was further found
that pre-pregnancy obesity was an independent risk fac-
tor for low Apgar scores. Therefore, it is important that
clinicians consider maternal obesity alone as an inde-
pendent risk factor for adverse pregnancy outcomes.
Overall, it is important to note that associations with
A p g a r< 7w e r em o d e s t( O R<2 . 0 )f o ra l lf a c t o r s ,e v e n
those with high statistical significance, indicating weak
evidence of true associations.
There are three limitations to this paper that should
be addressed in future investigations. First, the database
does not identify the ethnicity of the women in the sam-
ple. According to available 1996 and 2006 Canadian
Census [25,26], the ethnic distribution of London has
changed modestly between those two years. Previous
studies have demonstrated that ethnicity did have a
small impact on prevalence of MDG, however, did not
fully explain time trends in MDG [3-11]. Since we were
not able to assess whether control for ethnicity might
modify the estimated impact of other factors in our ana-
lyses, the influence of ethnicity on our findings cannot
be completely ruled out.
The second limitation of the study was that the data-
base did not indicate if all women in our cohort were
screened for GDM. In Canada, it is recommended that
all women be screened between 24-28 weeks gestation
based on national guidelines by the Canadian Diabetes
Association [1,2]. However, the main goal of the present
study was to examine the relationship between changing
prevalence of maternal glucose disorders and obesity.
Therefore, we feel that this is a significant step forward
in our understanding of why maternal glucose disorders
are increasing in the obstetrical population.
Finally, height and weight data contributing to the cal-
culation came from variable sources, including self-
report, therefore misreporting will have influenced the
accuracy of BMI. We speculate it may have produced an
underestimate in BMI. However, this underestimate is
likely to be non-differential in regards to year, and
therefore this would not explain the negative finding.
Conclusion
This is the first study to investigate the relationship
between increasing prevalence of maternal glucose dis-
orders and obesity. Contrary to our hypothesis, the
results of the present study indicated that the rising pre-
valence of maternal glucose disorders is not related to
increasing BMI.
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